CPT code 86480 represents a laboratory immunologic assay that measures the gamma interferon antigen response to tuberculosis antigens, evaluating cell-mediated immunity. This test is used clinically to detect immune sensitization to TB and can inform diagnostic pathways for latent or active infection. Nationally, the code matters because TB screening and diagnosis rely on scalable, standardized laboratory methods that affect public health surveillance and clinical management.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the assay, commonly associated sites of service, and the scope of reimbursement considerations across major payers. The publication summarizes available benchmarks, coding guidance, and pertinent policy updates affecting coverage and billing for interferon-gamma release assays.

The report provides practical reference material for billing staff, laboratory managers, and compliance teams by outlining the clinical purpose of the test, typical practice settings, and the payer landscape. Data not available in the input is noted where applicable.